ストックスクリーナーアプリを入手
1.47
8.89%
0.12
アフターアワーズ：
1.47
Durect Corp (DRRX) 最新ニュース
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
Durect Corp (NQ: DRRX - Financial Content
Durect (FRA:DC8A) Total Inventories : €2.30 Mil (As of Jun. 2024) - GuruFocus.com
DURECT Co. (NASDAQ:DRRX) Expected to Post Q3 2024 Earnings of ($0.14) Per Share - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corp reports steady Q2 financials, plans Phase III trial - Investing.com India
Durect: Q2 Earnings Snapshot - Houston Chronicle
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT (DRRX) Set to Announce Quarterly Earnings on Tuesday - Defense World
DURECT Co. (NASDAQ:DRRX) Receives $27.50 Average Target Price from Brokerages - American Banking and Market News
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - StockTitan
ProAssurance Co. (NYSE:PRA) Shares Bought by CANADA LIFE ASSURANCE Co - Defense World
DURECT (DRRX) Stock Price, News & Analysis - MarketBeat
Altair Engineering (NASDAQ:ALTR) Stock Rating Lowered by The Goldman Sachs Group - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above Two Hundred Day Moving Average of $1.13 - MarketBeat
DURECT Co. (NASDAQ:DRRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above 200-Day Moving Average of $1.01 - Defense World
Durect - The Pharma Letter
DURECT Corporation Announces Presentations in Upcoming Investor Conferences - Quantisnow
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol ... - Quantisnow
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Are Medical Stocks Lagging DURECT (DRRX) This Year? - Yahoo Canada Finance
Short Interest in DURECT Co. (NASDAQ:DRRX) Increases By 15.1% - MarketBeat
DURECT Co. (NASDAQ:DRRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
DURECT Co. (NASDAQ:DRRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Drug ManufacturersOther Equities Technical Momentum -- DepoMed, Pernix Therapeutics Holdings, Novo Nordisk ... - br.ADVFN.com
DURECT Corporation Announces Update on DUR-928 Development Program - br.ADVFN.com
Financial Metrics Exploration: Understanding Durect Corp (DRRX) Through Ratios – DWinneX - The Dwinnex
DURECT (NASDAQ:DRRX) Stock Crosses Above Two Hundred Day Moving Average of $0.86 - Defense World
Durect Corp’s Mixed Bag: Up 110.54% in 6 Months, Up 60.25% in 30 Days - The InvestChronicle
Durect stock eyes by H.C Wainwright despite FDA's breakthrough drug designation - Investing.com
FDA grants Breakthrough Therapy status for DURECT's larsucosterol - Investing.com
DURECT gets FDA breakthrough therapy status for larsucosterol (NASDAQ:DRRX) - Seeking Alpha
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated ... - Yahoo Finance
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - PR Newswire
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.12% - MSN
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.12% - MSN
Q2 2024 EPS Estimates for DURECT Co. Lifted by Analyst (NASDAQ:DRRX) - Defense World
DURECT Co. to Post FY2024 Earnings of ($0.90) Per Share, Northland Capmk Forecasts (NASDAQ:DRRX) - Defense World
Brokers Set Expectations for DURECT Co.'s Q2 2024 Earnings (NASDAQ:DRRX) - Defense World
Disclosure of trading in own shares from May 2nd to May 8th, 2024 - Yahoo Finance Australia
Holland America Line Opens Bookings for 2026 Grand World Voyage, Unveils 2026 Grand Australia and New Zealand ... - Yahoo Finance Australia
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q1 2024 results By Investing.com - Investing.com Australia
Earnings call: DURECT Corporation reports Q1 2024 results - Investing.com India
Exploring Three ASX Growth Companies With High Insider Ownership - Yahoo Finance UK
Top German Growth Companies With High Insider Ownership In May 2024 - Yahoo Finance Australia
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - PR Newswire
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Canada Finance
State Street Corporation's (NYSE:STT) CEO Might Not Expect Shareholders To Be So Generous This Year - Yahoo Finance Australia
Truist Financial Corp Has $2.56 Million Position in iShares Yield Optimized Bond ETF (NYSEARCA:BYLD) - Defense World
0.88%
0.42%
大文字化:
|
ボリューム (24 時間):